How to buy Kindred Biosciences stock | $3.71

Kindred Biosciences, Inc is a drug manufacturers-specialty & generic business based in the US. Kindred Biosciences shares (KIN) are listed on the NASDAQ and all prices are listed in US Dollars. Kindred Biosciences employs 156 staff and has a trailing 12-month revenue of around USD$3.9 million.

How to buy shares in Kindred Biosciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Kindred Biosciences. Find the stock by name or ticker symbol: KIN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kindred Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$3.71, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kindred Biosciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Kindred Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kindred Biosciences share price

Use our graph to track the performance of KIN stocks over time.

Kindred Biosciences shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$3.71
52-week range	USD$3.105 - USD$11.93
50-day moving average	USD$3.9369
200-day moving average	USD$4.1515
Wall St. target price	USD$11.18
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.634

Buy Kindred Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Kindred Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kindred Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kindred Biosciences price performance over time

Historical closes compared with the close of $3.71 from 2020-12-09

1 week (2021-01-11)	-23.03%
1 month (2020-12-18)	-10.17%
3 months (2020-10-16)	-13.52%
6 months (2020-07-17)	-10.82%

1 year (2020-01-17)	-62.30%
2 years (2019-01-18)	-62.34%
3 years (2018-01-18)	8.75
5 years (2016-01-15)	12.77%

Kindred Biosciences financials

Revenue TTM	USD$3.9 million
Gross profit TTM	USD$3.7 million
Return on assets TTM	-32.39%
Return on equity TTM	-31.01%
Profit margin	0%
Book value	$1.944
Market capitalisation	USD$183.4 million

TTM: trailing 12 months

Shorting Kindred Biosciences shares

There are currently 712,705 Kindred Biosciences shares held short by investors – that's known as Kindred Biosciences's "short interest". This figure is 3% up from 691,979 last month.

There are a few different ways that this level of interest in shorting Kindred Biosciences shares can be evaluated.

Kindred Biosciences's "short interest ratio" (SIR)

Kindred Biosciences's "short interest ratio" (SIR) is the quantity of Kindred Biosciences shares currently shorted divided by the average quantity of Kindred Biosciences shares traded daily (recently around 195798.07692308). Kindred Biosciences's SIR currently stands at 3.64. In other words for every 100,000 Kindred Biosciences shares traded daily on the market, roughly 3640 shares are currently held short.

However Kindred Biosciences's short interest can also be evaluated against the total number of Kindred Biosciences shares, or, against the total number of tradable Kindred Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kindred Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Kindred Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0235% of the tradable shares (for every 100,000 tradable Kindred Biosciences shares, roughly 24 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kindred Biosciences.

Find out more about how you can short Kindred Biosciences stock.

Kindred Biosciences share dividends

We're not expecting Kindred Biosciences to pay a dividend over the next 12 months.

Kindred Biosciences share price volatility

Over the last 12 months, Kindred Biosciences's shares have ranged in value from as little as $3.105 up to $11.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kindred Biosciences's is 1.2184. This would suggest that Kindred Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Kindred Biosciences overview

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

Frequently asked questions

• What percentage of Kindred Biosciences is owned by insiders or institutions?

  Currently 6.161% of Kindred Biosciences shares are held by insiders and 67.763% by institutions.

• How many people work for Kindred Biosciences?

  Latest data suggests 156 work at Kindred Biosciences.

• When does the fiscal year end for Kindred Biosciences?

  Kindred Biosciences's fiscal year ends in December.

• Where is Kindred Biosciences based?

  Kindred Biosciences's address is: 1555 Bayshore Highway, Burlingame, CA, United States, 94010

• What is Kindred Biosciences's ISIN number?

  Kindred Biosciences's international securities identification number is: US4945771099

• What is Kindred Biosciences's CUSIP number?

  Kindred Biosciences's Committee on Uniform Securities Identification Procedures number is: 494577109